Effects of cisapride on oesophageal transit of solids in patients with progressive systemic sclerosis

S. J. Wang*, J. L. Lan, J. L. Lan, D. Y. Chen, Y. H. Chen, T. Y. Hsieh, W. Y. Lin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

In most patients with progressive systemic sclerosis (PSS) the oesophagus is affected. Reflux symptoms are most frequent, whilst dysphagia also occurs. Cisapride, a prokinetic agent, may enhance motility along the gastrointestinal tract. The effects of cisapride on oesophageal transit were evaluated in 12 PSS patient using a solid-phase radionuclide oesophageal transit study. Each PSS patient was given cisapride 10 mg or placebo orally three times a day in a random, double-blind, crossover fashion. The results show that cisapride does not seem to have any impact on oesophageal transit in patients with PSS.

Original languageEnglish
Pages (from-to)43-45
Number of pages3
JournalClinical Rheumatology
Volume21
Issue number1
DOIs
StatePublished - 2002

Keywords

  • Cisapride
  • Motility
  • Oesophageal transit study
  • Progressive systemic sclerosis

Fingerprint

Dive into the research topics of 'Effects of cisapride on oesophageal transit of solids in patients with progressive systemic sclerosis'. Together they form a unique fingerprint.

Cite this